Discrepancy between disease activity and levels of vascular endothelial growth factor in a patient with POEMS syndrome successfully treated with autologous stem-cell transplantation

Bone Marrow Transplantation

Volumn 42, Issue 9, 2008, Pages 627-629

  Goto, H ^a   Nishio, M ^a   Kumano, K ^a   Fujimoto, K ^a   Yamaguchi, K ^a   Koike, T ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; IMMUNOGLOBULIN G; MELPHALAN; PREDNISONE; VASCULOTROPIN;

ADULT; ASCITES; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; KIDNEY DISEASE; LABORATORY TEST; LETTER; MOTOR NEUROPATHY; OLIGURIA; PLEURA EFFUSION; POEMS SYNDROME; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SENSORY NEUROPATHY; SKIN MANIFESTATION; STEM CELL MOBILIZATION; THYROID FUNCTION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PLASMACYTOMA; POEMS SYNDROME; TRANSPLANTATION CONDITIONING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56349092810     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.223     Document Type: Letter

References (12)

1. Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21: 1390-1397.
2. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005; 106: 1135.
3. Kanai K, Kuwabara S, Misawa S, Hattori T. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 2007; 46: 311-313.
4. Samaras P, Bauer S, Stenner-Liewen F, Steiner R, Zweifel M, Renner C et al. Treatment of POEMS syndrome with bevacizumab. Haematologica 2007; 92: 1438-1439.
5. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006; 107: 4972-4973; author reply 4973-4974.
6. Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 2008; 19: 595.
7. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004; 104: 3400-3407.
8. Jouve P, Humbert M, Chauveheid MP, Jais X, Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med 2007; 101: 353-355.
9. Niimi H, Arimura K, Jonosono M, Hashiguchi T, Kawabata M, Osame M et al. VEGF is causative for pulmonary hypertension in a patient with Crow-Fukase (POEMS) syndrome. Intern Med 2000; 39: 1101-1104.
10. Sanada S, Ookawara, S, Karube H, Shindo T, Goto T, Nakamichi T et al Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. Am J Kidney Dis 2006; 47: 672-679.
11. Kuwabara S, Misawa S, Kanai K, Kikkawa Y, Nishimura M, Nakaseko C et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006; 66: 105-107.
12. Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007; 110: 1075-1076.